On May 3, 2017, after the process of project inspection, interview, product verification, due diligence, signing of investment agreement, capital injection, etc., Hangzhou Chende Investment Co., Ltd. and Guangzhou Jinyuan Investment Management Co., Ltd. (Guangzhou Jinyu Medical Inspection Group is the fund investor and manager of the fund)’s tens of millions of equity investments in BioPredia are all in place, and two fund companies are formally became shareholders of BioPredia BioTech Co., Ltd.
According to the investment agreement and the company's articles of association, the company changed its registered capital to RMB 13.6364 million, and identified Tao Wenjing, Huang Aihua, Tao Fangyu, Wang Fengshun, and Wu Jialu as members of the company's board of directors. Tao Wenjing is the company's legal representative, chairman and general manager.